Castle Biosciences
CSTL
159 hedge funds and large institutions have $549M invested in Castle Biosciences in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 50 reducing their positions, and 23 closing their positions.
326% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $2.83M
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
39% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 23
5% more funds holding
Funds holding: 151 → 159 (+8)
8% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 50
0.41% more ownership
Funds ownership: 90.99% → 91.41% (+0.41%)
1% less capital invested
Capital invested by funds: $553M → $549M (-$3.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$9.27M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$3.73M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$3.42M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$12.7M |
| 2 |
Morgan Stanley
New York
|
-$8.94M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$4.97M |
| 4 |
Millennium Management
New York
|
-$4.76M |
| 5 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$3.7M |
CSTL Hedge Fund Activity: Q2 2024 in Review
159 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q2 2024, worth a combined $549M — down 0.7% from $553M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CSTL positions and 23 closed out — a net gain of 9 holders — while 54 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock, adding an estimated $10M. The largest seller was Granahan Investment Management, cutting an estimated $12.7M.
- 159 institutional investors held Castle Biosciences (CSTL) as of Q2 2024, up from 151 in Q1 2024.
- Funds reported $549M of Castle Biosciences stock for Q2 2024, down 0.7% quarter-over-quarter.
- 32 funds opened new Castle Biosciences positions in Q2 2024 and 23 closed out, a net change of +9 holders.
- The largest Castle Biosciences buyer in Q2 2024 was BlackRock, an estimated $10M added.
- The largest Castle Biosciences seller in Q2 2024 was Granahan Investment Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2024.